---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-24-002520"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:24:03.366923+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Entera Bio Q2 2024 net loss $2.1M; cash runway into Q3 2025; EB613 milestone expected

## Summary
- Net loss of $2.1M ($0.06 per share) vs $2.3M ($0.08) in Q2 2023; cash $9.1M at June 30, 2024.
- R&D expenses $1.1M (down $0.1M YoY); G&A flat at $1.1M; operating expenses $2.2M.
- EB613 (oral PTH) Phase 2 data published in JBMR; FDA SABRE endpoint ruling expected ~5 months.
- EB612 hypoparathyroidism Phase 1 data at ENDO 2024; potential move to Phase 2 soon.
- Collaboration with OPKO on oral GLP-2 (short bowel) and GLP-1/glucagon (obesity) ongoing; PK data due H2 2024.

## SEC filing metadata
- accession: 0001178913-24-002520
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891324002520/0001178913-24-002520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891324002520/zk2431821.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-24-002520
- JSON: https://secwatch.observer/filing/0001178913-24-002520.json
- Plain text: https://secwatch.observer/filing/0001178913-24-002520.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.